FIELD: medicine.
SUBSTANCE: essence of the invention includes a way of inhibition of a mammal cancer cell with the defective antiviral response sensitive to interferon, including introduction of myxoma virus in a cell. The myxoma virus can be used at cancer treatment.
EFFECT: simplification of a way.
35 cl, 1 ex, 28 dwg, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| USE OF COMBINATION OF MYXOMA VIRUS AND RAPAMYCIN FOR THERAPEUTIC TREATMENT | 2006 |
|
RU2461630C2 |
| THERAPEUTIC COMPOSITIONS AND METHODS OF USING FOR TREATING CANCER | 2016 |
|
RU2720984C2 |
| USE OF GENETICALLY MODIFIED PATHOGENIC MEASLES VIRUS WITH IMPROVED APOPTOTIC PROPERTIES (MV-DELTAC VIRUS) IN CANCER THERAPY | 2014 |
|
RU2700083C2 |
| M2-DEFECTIVE POXVIRUS | 2019 |
|
RU2819245C2 |
| DESIGNING OF CARCINOLYTIC ADENOVIRUS RECOMBINANT, SPECIFICALLY EXPRESSING IMMUNOMODULATORY FACTOR GM-CSF IN TUMORAL CELLS AND ITS APPLICATION | 2004 |
|
RU2361611C2 |
| CELL ELIMINATION BY USING VIRUSES | 2001 |
|
RU2270685C2 |
| CEREBRAL CANCER TREATMENT WITH ONCOLYTIC ADENOVIRUS | 2014 |
|
RU2689553C2 |
| COATED ONCOLYTIC ADENOVIRUS FOR ANTICANCER VACCINES | 2015 |
|
RU2695375C2 |
| ONCOLYTIC ADENOVIRUS FOR TREATING CANCER, USING IT, AND PHARMACEUTICAL COMPOSITION CONTAINING IT | 2010 |
|
RU2536931C2 |
| ADENOVIRAL VECTORS AND RELATED METHODS AND APPLICATIONS | 2009 |
|
RU2520823C2 |
